BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling